BiotechTube

V212 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster, Herpes Zoster-related Complications

Trial Timeline

Nov 2, 2007 → Jan 26, 2010

NCT ID
NCT00535236

About V212 + Placebo

V212 + Placebo is a phase 1 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00535236. Target conditions include Herpes Zoster, Herpes Zoster-related Complications.

What happened to similar drugs?

8 of 20 similar drugs in Herpes Zoster were approved

Approved (8) Terminated (1) Active (11)
✅Zoster Vaccine, Live + Comparator: placeboMerckApproved
✅Zoster Vaccine LiveMerckApproved
✅ZOSTAVAX®MerckApproved
✅FamciclovirNovartisApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01527383Phase 2Completed
NCT01254630Phase 3Completed
NCT00535236Phase 1Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
35
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
29